YALE UNIVERSITY

Achieve Life Sciences has named Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Dr. Cindy Jacobs as the company advances its smoking cessation drug cytisinicline.

Apple's new hypertension notification feature for Apple Watch Series 9 and later models has received FDA approval and will launch with watchOS 26 on September 15.

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.

Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.

Berlin Cures' Phase 2 trial of BC 007 (rovunaptabin) for long COVID failed in November 2024 due to poor patient selection and inadequate outcome measures, despite some participants experiencing dramatic symptom improvements.

Yale researchers developed TMAB3, a specially engineered antibody that successfully delivers RNA therapies to treatment-resistant "cold" tumors, significantly reducing tumor size and extending survival in animal models of pancreatic, brain, and skin cancers.

Yiviva's Phase 2b study demonstrated that YIV-906 plus sorafenib significantly improved median overall survival to 14.3 months versus 7.5 months with sorafenib alone in HBV-positive advanced hepatocellular carcinoma patients.

UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.

Non-human primate studies reveal that increasing Ifenprodil doses from 20 mg to 40-80 mg could achieve 60-80% receptor occupancy, significantly enhancing therapeutic effects for chronic cough treatment.

Brooklyn Health secured $6.5 million in seed funding led by HealthX Ventures to advance its AI-powered clinical trial measurement technology for central nervous system disorders.